Detection of K‐ras gene mutation by liquid biopsy in patients with pancreatic cancer

Abstract

BACKGROUND: Cell-free circulating tumor DNA (ctDNA) in serum has been considered to be a useful candidate for noninvasive cancer diagnosis. The current study was designed to estimate the clinical usefulness of genetic analysis for ctDNA by digital polymerase chain reaction in patients with pancreatic cancer. METHODS: The authors compared K-ras mutations detected in endoscopic ultrasound-guided fine-needle aspiration biopsy tissue DNA and in ctDNA from 75 patients with pancreatic cancer. K-ras mutations in the serum of 66 independent, consecutive patients with pancreatic cancer were also analyzed and the authors compared the results with survival rates. RESULTS: The frequencies of the mutations in tissue samples at G12V, G12D, and G12R in codon 12 were 28 of 75 samples (37.3%), 22 of 75 samples (29.3%), and 6 of 75 samples (8.0%), respectively. Conversely, the rates of the mutations in ctDNA were 26 of 75 samples (34.6%), 29 of 75 samples (38.6%), and 4 of 75 samples (5.3%), respectively. Overall, the K-ras mutation rates in tissue and ctDNA were 74.7% and 62.6%, respectively, and the concordance rate between them was 58 of 75 samples (77.3%). Survival did not appear to differ by the presence of K-ras mutations in tissue DNA, but the survival of patients with K-ras mutations in ctDNA was significantly shorter than that of patients without mutations in both a development set (P 5.006) and an independent validation set (P 5.002). The difference was especially evident in cases with a G12V mutation. CONCLUSIONS: Analysis of ctDNA is a new useful procedure for detecting mutations in patients with pancreatic cancer. This noninvasive method may have great potential as a new strategy for the diagnosis of pancreatic cancer as well as for predicting survival.

Switch in KRAS mutational status during an unusual course of disease in a patient with advanced pancreatic adenocarcinoma: implications for translational research

“…As KRAS is not yet established as a clinically relevant biomarker in PDAC, future translational trials in pancreatic cancer that evaluate a broad range of novel biomarkers should, at least to our opinion, include a repeated biomarker assessment during the course of disease within their prospective study protocols. Novel promising techniques like liquid biopsy approaches may thereby help to overcome the limitations of obtaining tumor tissue safely in PDAC [25]. As it may be difficult to obtain sufficient tumor tissue in PDAC by percutaneous- or endosonography-guided biopsy techniques, a sampling error may occur specifically in the light of tumor heterogeneity.…”

Advancing Aptamers as Molecular Probes for Cancer Theranostic Applications—The Role of Molecular Dynamics Simulation

“…Epidermal growth factor receptor is the most common biomarker used to diagnose these rare cancers . However, certain specific receptors such as tyrosine protein kinase Met (MET) and ROS1 have been found as biomarkers for rare types of cancers . In spite of these receptors as biomarkers, specificity remains as a major challenge for targeted cancer treatments.…”

Novel Diagnostic and Predictive Biomarkers in Pancreatic Adenocarcinoma

“…Kinugasa et al demonstrated that the measurements of KRAS mutation in patients with pancreatic cancer appeared to be an early monitoring tool for treatment efficacy [30]. Our initial pilot study in patients with pancreatic cancer demonstrated cf DNA could detect responses reliably prior to changes seen on conventional imaging [40].…”